Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Holdings Increased by State Street Corp

State Street Corp boosted its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 52.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,353 shares of the biotechnology company’s stock after buying an additional 7,680 shares during the quarter. State Street Corp owned approximately 0.39% of Atara Biotherapeutics worth $182,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the last quarter. FMR LLC increased its holdings in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the second quarter valued at about $79,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics in the second quarter valued at about $53,000. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Stock Up 15.5 %

Shares of ATRA stock opened at $16.35 on Friday. The business has a 50 day moving average of $11.72 and a two-hundred day moving average of $9.61. The company has a market cap of $94.18 million, a P/E ratio of -0.63 and a beta of 0.51. Atara Biotherapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the firm posted ($16.50) earnings per share. Analysts expect that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ATRA shares. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. RODMAN&RENSHAW upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group lifted their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Atara Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $18.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.